Key result
ASC-CMed reduced IL-1β/TGF-β2-induced endothelial-mesenchymal transition in HUVECs, evidenced by reduced expression of mesenchymal markers like TAGLN (P=0.0008), but did not restore angiogenesis.
Why the study?
Endothelial-mesenchymal transition yields up to 25% of cardiac myofibroblasts in ischaemic hearts, and ASC conditioned medium blocks fibroblast activation, prompting testing of whether it abrogates EndMT.
Does ASC-CMed abrogate EndMT and prevent the formation of adverse myofibroblasts in HUVEC treated with IL-1β/TGF-β2?
Does ASC-CMed abrogate EndMT and prevent the formation of adverse myofibroblasts in HUVEC treated with IL-1β/TGF-β2?
p-value: p=0.0008
ASC-CMed reduces IL-1β/TGF-β2-induced EndMT in vitro by decreasing mesenchymal markers, supporting its potential anti-fibrotic effects, though it does not restore endothelial function.
OBJECTIVES: Endothelial cells undergo TGF-β-driven endothelial-mesenchymal transition (EndMT), representing up to 25% of cardiac myofibroblasts in ischaemic hearts. Previous research showed that conditioned medium of adipose tissue-derived stromal cells (ASC-CMed) blocks the activation of fibroblasts into fibrotic myofibroblasts. We tested the hypothesis that ASC-CMed abrogates EndMT and prevents the formation of adverse myofibroblasts. MATERIALS AND METHODS: Human umbilical vein endothelial cells (HUVEC) were treated with IL-1β and TGF-β2 to induce EndMT, and the influence of ASC-CMed was assessed. As controls, non-treated HUVEC or HUVEC treated only with IL-1β in the absence or presence of ASC-CMed were used. Gene expression of inflammatory, endothelial, mesenchymal and extracellular matrix markers, transcription factors and cell receptors was analysed by RT-qPCR. The protein expression of endothelial and mesenchymal markers was evaluated by immunofluorescence microscopy and immunoblotting. Endothelial cell function was measured by sprouting assay. RESULTS: IL-1β/TGF-β2 treatment induced EndMT, as evidenced by the change in HUVEC morphology and an increase in mesenchymal markers. ASC-CMed blocked the EndMT-related fibrotic processes, as observed by reduced expression of mesenchymal markers TAGLN (P = 0.0008) and CNN1 (P = 0.0573), as well as SM22α (P = 0.0501). The angiogenesis potential was impaired in HUVEC undergoing EndMT and could not be restored by ASC-CMed. CONCLUSIONS: We demonstrated that ASC-CMed reduces IL-1β/TGF-β2-induced EndMT as observed by the loss of mesenchymal markers. The present study supports the anti-fibrotic effects of ASC-CMed through the modulation of the EndMT process.
No takes yet. Share an insight, caveat, or question.
Liguori et al. (2019) studied Endothelial-mesenchymal transition. Conditioned medium of adipose tissue-derived stromal cells (ASC-CMed) vs. Non-treated HUVEC or HUVEC treated only with IL-1β/TGF-β2 was evaluated on Expression of mesenchymal markers and angiogenesis potential (p=0.0008). ASC-CMed reduced IL-1β/TGF-β2-induced endothelial-mesenchymal transition in HUVECs, evidenced by reduced expression of mesenchymal markers like TAGLN (P=0.0008), but did not restore angiogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: